NGENF News and Press, NervGen Pharma Corp From 05/20/21

Vancouver, British Columbia--(Newsfile Corp. - May 20, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company "), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system injuries, today reported its finan...

Vancouver, British Columbia--(Newsfile Corp. - May 12, 2021) -   NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (" NervGen " or the " Company "), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, announced th...

NervGen Pharma (NGENF) announces that the first subject has been dosed with nerve damage treatment NVG-291 in the company's Phase 1 clinical trial in healthy volunteers.The study, conducted in healthy subjects, is a two-part, triple-blind, randomized, placebo-controlled, first-in-hu...

Vancouver, British Columbia--(Newsfile Corp. - May 6, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, is pleased to announce ...

Vancouver, British Columbia--(Newsfile Corp. - May 4, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (" NervGen " the " Company "), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, announced that it has l...

Vancouver, British Columbia--(Newsfile Corp. - April 22, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, is pleased to announc...

NervGen Pharma (NGENF) has received approval and guidance from the Bellberry Human Research Ethics Committee ("HREC") in Australia on the design of a Phase 1 clinical trial for NVG-291, a specific and selective protein tyrosine phosphatase sigma ("PTPσ") inhibitor.The study p...

Remains on Track to Dose First Subjects in Q2 2021 Vancouver, British Columbia--(Newsfile Corp. - April 14, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage...

NervGen Pharma (NGENF): FY GAAP EPS of -$0.35.Cash and investments of $5.6M.The cash burn for the year ended December 31, 2020 from operating activities was approximately $6.4M.Press Release For further details see: NervGen Pharma reports FY results

Vancouver, British Columbia--(Newsfile Corp. - April 8, 2021) -   NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported i...